European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives
Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment
$1.5 billion invested in alternative proteins in 2020, including a record $435 million in the next pillar—fermentation
